Advice
Recommended for restricted use within NHS Scotland.
RECOMMENDATION
This licence extension has been granted on the basis of interim analyses which show superiority of imatinib over interferon combination therapy in terms of cytogenetic and haematological response.
Imatinib should be used only by or under the direction of haematologists/oncologists experienced in this field. There should be a formal process of audit and monitoring with a central registry of all patients receiving it and/or entry into a clinical trial.
Download detailed advice18KB (PDF)
Medicine details
- Medicine name:
- Imatinib (Glivec®)
- SMC ID:
- 26/02
- Indication:
- Chronic myeloid leukaemia
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 January 2003